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Abstract 24 
During hepatitis C virus (HCV) infection broadly neutralizing antibody (bNAb) responses targeting 25 
E1E2 envelope glycoproteins are generated in many individuals. It is unclear if these antibodies play a 26 
protective or a pathogenic role during chronic infection. In this study, we investigated whether bNAb 27 
responses in individuals with chronic infection were associated with differences in clinical 28 
2 
 
presentation. Patient-derived purified serum IgG was used to assess the breadth of HCV E1E2 binding 29 
and neutralization activity of HCV pseudoparticles. Two panels were compared, bearing viral 30 
envelope proteins representing either an inter-genotype or an intra-genotype (gt) 1 group.  We found 31 
that HCV viral load was negatively associated with strong cross-genotypic E1E2 binding (P=0.03). 32 
Overall we observed only modest correlation between total E1E2 binding and neutralizing ability. The 33 
breadth of inter-genotype neutralization did not correlate with any clinical parameters, however, 34 
analysis of individuals with gt 1 HCV infection (n=20), using an intra-genotype pseudoparticle panel, 35 
found a strong association between neutralization breadth and reduced liver fibrosis (P=0.006). Broad 36 
bNAb response in our chronic cohort was associated with a single nucleotide polymorphism (SNP) in 37 
the HLA-DQB1 gene (P=0.038) as previously reported in an acute cohort. Furthermore bNAbs in 38 
these individuals targeted more than one region of E2 neutralizing epitopes as assessed through cross-39 
competition of patient bNAbs with well-characterized E2 antibodies. We conclude that bNAb 40 
responses in chronic gt1 infection are associated with lower rates of fibrosis and host genetics may 41 
play a role in the ability to raise such responses. 42 
 43 
Importance 44 
Globally there are 130-150 million people with chronic HCV infection. Typically the disease is 45 
progressive and is a major cause of severe liver cirrhosis and hepatocellular carcinoma. While it is 46 
known that neutralizing antibodies have a role in spontaneous clearance during acute infection, little is 47 
known about their role in chronic infection. In the present work we investigate the antibody response 48 
in a cohort of chronically infected individuals and find that a broad neutralizing antibody response is 49 
protective, with reduced levels of liver fibrosis and cirrhosis. We also find an association with SNPs 50 
in class II HLA genes and the presence of a broad neutralizing response indicating that antigen 51 
presentation may be important for production of HCV neutralizing antibodies. 52 
 53 
 54 
 55 
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Introduction 56 
Hepatitis C virus (HCV) is a significant cause of liver morbidity and mortality worldwide (1). The 57 
majority (75%) of those infected proceed to chronic infection (2). Symptomatic acute HCV infection 58 
is rare; therefore HCV has the potential to spread undetected within those at risk. In countries with 59 
high prevalence, poor healthcare infrastructure and lack of funding make eradication of HCV unlikely 60 
through curative therapies alone (1, 3). Thus, effective preventative strategies are needed to achieve 61 
global eradication of the virus (4). 62 
 63 
Antibodies targeting the HCV envelope glycoproteins E1 and E2 can contribute significantly to viral 64 
clearance in HCV infection (5, 6). These proteins are responsible for virus attachment and entry into 65 
host cells through interaction with the receptors SR-B1, CD81, Claudin and Occludin (7-10). Previous 66 
observational studies have shown rapid onset of anti-HCV antibodies to be associated with higher 67 
likelihood of clearance (11). More recently, it has been proposed that developing an antibody profile 68 
capable of neutralizing diverse HCV strains (broadly neutralizing) predicts acute clearance in a cohort 69 
infected with gt1a HCV (12). Further studies have suggested that broadly neutralizing antibodies 70 
(bNAbs) may be able to control levels of virus and contribute to clearance even after infection has 71 
become established (13). In one case of a chronically infected patient who spontaneously cleared 72 
HCV, a bNAb response was generated, initially with subsequent restoration of T cell activity and 73 
resolution of infection (5).  74 
 75 
Only a small number of individuals with bNAbs have been studied in detail with little information on 76 
the regions of the E1E2 glycoproteins that are preferentially targeted by these antibodies. This has 77 
largely involved epitope-mapping of patient-derived monoclonal antibodies (mAbs) (14-16). Human 78 
neutralizing and non-neutralizing mAbs have been used to identify distinct immunogenic domains of 79 
E1E2 (15, 17-21). However, in vivo, a polyclonal response is generated which may target multiple 80 
regions of the envelope proteins. A recent study demonstrated that some HCV-infected individuals 81 
largely target one immunogenic domain whereas others produce antibody responses to multiple 82 
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domains (21). The importance of interplay of antibodies binding different epitopes has not been fully 83 
explored, although there are conflicting reports of some antibodies conferring additive or interfering 84 
effects on virus neutralization (22, 23).  85 
 86 
While diverse HCV strains are usually categorized by genotype, this does not correlate well with 87 
sensitivity to neutralization by mAbs (24, 25). The genetic diversification of HCV, both within and 88 
between hosts, introduces the potential to escape from monoclonal bNAbs with several studies 89 
reporting naturally occurring, single amino acid (aa) mutations conferring escape (18, 26). The recent 90 
E2 crystal structures (27, 28) provide evidence that antibody resistance is complex with mutations 91 
distant from the targeted epitope affecting antibody binding, presumably through structural changes 92 
(26). Therefore, further studies of the antibody response to a varied range of envelope proteins in vivo 93 
are required. As animal models of HCV infection and adaptive immunity are suboptimal, we can still 94 
gain useful information from studying the humoral responses of chronically infected individuals using 95 
in vitro models. 96 
 97 
Although there is evidence that bNAbs have clinical relevance in acute infection, their role in chronic 98 
infection is not clear. Indeed, the immune response to HCV can have pathological consequences as 99 
seen in cryoglobulinaemic vasculitis (29). If large scale vaccination was to be considered, it is 100 
important to determine that stimulating such a response will not be harmful in the event of an 101 
authentic infection. Studying clinical associations in patients with bNAbs can reveal potential adverse 102 
outcomes and yield insights into factors associated with NAb production.  103 
 104 
In this study, we investigate bNAb responses in chronically infected HCV (CHCV) patients, 105 
determine any association with clinical and host factors, and characterize the epitopes targeted by 106 
these antibodies. We identify an association between bNAb response and less severe liver disease and 107 
show that a bNAb response targets multiple neutralizing E2 epitopes within different 108 
immunodomains. We also report an association between bNab response and age, however no 109 
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association with estimated duration of infection or age at infection was found. Finally, we confirm 110 
that SNP rs2395522 in the HLA-DQ gene is strongly associated with production of a bNAb response. 111 
 112 
Methods 113 
Patient characteristics. Subjects with either gt1 or gt3 CHCV were prospectively recruited from 3 114 
local liver clinics. Individuals with co-existing liver pathologies, body mass index (BMI) ≥ 31 or 115 
hepatocellular carcinoma were excluded. Healthy controls with no liver pathologies or significant co-116 
morbidities were also recruited and their samples used as negative controls in subsequent 117 
experiments.  All subjects completed a symptom questionnaire, clinical details were recorded and 118 
baseline biochemistry, virology and Interleukin-28B (rs12979860) profiles were determined. Liver 119 
stiffness was measured by transient elastography using a Fibroscan (Echosens). Serum and whole 120 
blood samples were obtained and stored at -70°C. Ethical approval was granted for this study by the 121 
West of Scotland Research Ethics Committee and all patients gave informed consent. 122 
 123 
Cell lines. Human hepatoma Huh-7 cells, Huh7-J20 cells (30) and human epithelial kidney 293T cells 124 
were grown in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal calf serum, 5% 125 
nonessential amino acids, Penicillin, Streptomycin and 200 mM L-glutamine. Huh7-J20 cells were 126 
supplemented with 2μg/ml puromycin. 127 
 128 
Antibodies. The anti-E2 human monoclonal antibodies (HmAb) CBH-4B, CBH-7, HC-1, HC-11 and 129 
HC-84 (31-33) were a generous gift from Steven Foung. The anti-E2 mouse mAb AP33 has been 130 
described previously (34). 131 
 132 
E1E2 binding assay. The enzyme-linked immunosorbent assay (ELISA) to detect antibody binding 133 
to HCV glycoproteins was performed as described (35). Briefly, HCV glycoproteins in lysates of 134 
HEK-293T cells transfected with E1E2 expression plasmids were captured onto Galanthus nivalis 135 
agglutinin (GNA) coated Immulon II plates (Thermolabsystems). Protein G-purified patient IgG was 136 
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isolated from serum using the Nab protein G spin kit (Thermoscientific) and the concentration was 137 
quantified by absorbance at 280nm. Purified patient IgG was added at 200 µg/ml in PBS containing 138 
0.05% Tween-20 and 2% Skimmed Milk Powder (PBSTM) and bound antibodies were detected using 139 
HRP-conjugated anti-human IgG antibody (Sigma A0170) and TMB (3,3, 5, 5’-tetramethylbenzidine, 140 
Sigma) substrate. Two representative healthy control samples were included for quality control 141 
purposes. A dilution curve of mAb AP33 that binds to a highly conserved linear epitope was also 142 
included to enable comparison between plates. Absorbance values were measured at 450 nm and 143 
normalized according to the AP33 curve to give a value representing the concentration of AP33 (in 144 
µg/ml) which gave the same absorbance as the test sample.  145 
 146 
Generation of HCV pseudoparticles (HCVpp), infectious virus (HCVcc) and neutralization 147 
assays. HEK-293T cells were co-transfected with plasmids expressing murine moloney leukaemia 148 
virus (MLV) Gag-pol, the MLV transfer vector carrying firefly luciferase reporter and plasmid 149 
expressing the relevant HCV E1E2. After 72 h, the medium was harvested, filtered through a 0.45 µM 150 
membrane and used as a source of HCVpp as described (36). Infectious virus was produced in Huh7 151 
cells by electroporation of RNA encoding full-length JFH-1 or chimeric JFH-1. The intra-genotypic 152 
chimera 2B.1.1/JFH1 and the inter-genotypic chimera HQL (1a H77/JFH1) have been described 153 
previously (20, 30). For neutralization assays, HCVpp and purified patient IgG at 100 µg/ml 154 
(equivalent to serum dilution of 1:100-1:250 based on the known IgG levels in chronic HCV patient 155 
sera (37)) were mixed and incubated for 1 h at 37°C, then used to infect Huh7 cells for 4 h. The 156 
inoculum was removed and fresh media was added. Cells were lysed 3 days post-infection and 157 
infectivity assessed using the GloLysis Luciferase assay (Promega). Similarly, neutralization of 158 
HCVcc infection was tested in Huh7-J20 cells and infectivity assessed 3 days post-infection using the 159 
Phospha-Light assay system (Thermofisher) to measure secretory alkaline phosphatase (SEAP) levels 160 
(30). 161 
 162 
Amplification of viral E1E2 sequences derived from patients. A cDNA library was created from 163 
HCV RNA isolated from patient serum using the QiaAMP Viral RNA mini kit (Qiagen). The 164 
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complete E1E2-encoding region was amplified using degenerate nested primers (Gt1 outer sense 5′ 165 
GTGAAYTAYGCRACAGGGAA, Gt1 outer antisense 5′GCAAAGCAGAARAACACGAG, Gt1 166 
inner sense 5′CACCATGGGTTGCTCYTTYTCTATCTTC, Gt1 inner antisense 5′ 167 
AAAGTTTCTAGATTACYGCCTCYGCYTGGGAKA) and cloned into the phCMV expression 168 
vector using the Gateway recombination cloning system (Invitrogen). 169 
  170 
DNA isolation and SNP analysis. DNA was extracted from whole blood using the QiAMP DNA 171 
Mini Kit (Qiagen). Custom primers for SNP rs2395522 and reporter dye mix (ThermoFisher) were 172 
included in a qPCR reaction using Taq mastermix on a 7500HT Fast Real-Time PCR system (Applied 173 
Biosystems).  Samples were assigned as A/T heterozygotes or AA or TT homozygotes according to 174 
the fluorescence signal. 175 
 176 
Epitope targeting. A soluble form of gt1a E2 (H77) protein (sE2) was purified following expression 177 
in High Five insect cells. Immulon II plates were coated with sE2 at 1 µg/ml and incubated with 178 
purified patient IgG at 200 µg/ml in PBSTM. Subsequently, biotinylated antibodies to known epitopes 179 
were added at a concentration close to their half maximal effective concentration (EC50) (14, 17, 18, 180 
38). Streptavidin-HRP was added and binding measured as above. The reduction in relative binding of 181 
each biotinylated antibody (calculated as percentage reduction in absorbance) on addition of patient 182 
IgG compared to PBSTM control was determined.  183 
 184 
Analysis. Results of assays and any statistical analysis of association with clinical features were 185 
conducted using GraphPad Prism 6 Software (GraphPad Software, California) and SPSS v. 19.09 186 
(IBM, New York). Statistical comparisons were made using non-parametric tests (Chi Squared for 187 
categorical data, Wilcoxon Rank Sum for ordinal or numeric data) unless otherwise stated.  188 
 189 
 190 
 191 
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Results 192 
Cohort. Fifty-one HCV-infected patients (27 gt1, 24 gt3) from the CHCV cohort and 8 healthy 193 
controls were recruited. Demographics of the cohort are shown (Table 1). Apart from a higher 194 
prevalence of Asian ethnicity in the gt3 group (P=0.04), there were no significant differences in 195 
demographics between subjects infected with either gt1 or gt3 HCV.  196 
 197 
E1E2 HCVpp panels. To determine reactivity and neutralization of patient-derived IgG across a 198 
diverse range of envelope sequences, two panels of HCV pseudoparticles bearing test envelope 199 
proteins were used. The first, termed Panel XG, enabled analysis of antibody reactivity with E1E2 200 
proteins of different viral genotypes. This panel comprised E1E2 from 6 subgenotypes (39): gt1a 201 
H77c (Accession number: AF011751) , gt1b UKN1B5.23 (AY734976); gt2a JFH-1 (AB047639); 202 
gt2b, UKN 2B1.1 (AY734982); gt3a UKN3A13.6 (AY894683); gt4 UKN4.11.1 (AY734986). The 203 
second, termed Panel Gt1 was created to allow investigation of antibody reactivity within a single 204 
genotype as might arise during a natural infection. 103 patient-derived E1E2 sequences from eighteen 205 
gt1 HCV-infected patients collected from 3 cohorts across the UK (Trent HCV study group (40), St. 206 
Mary’s Acute Hepatitis C Cohort (41), Glasgow chronic HCV cohort (42)) were tested in the HCVpp 207 
system for infectivity (data not shown). As found previously in other studies not all sequences were 208 
infectious in this system (25, 43). 64% of the E1E2 sequences tested were functional giving a robust 209 
luciferase signal >10-fold above background. All the amino acid sequences were aligned in ClustalW, 210 
the best protein model with the lowest BIC score (16423.799) was used to generate a phylogenetic 211 
tree using the Maximum Likelihood method (Fig.1). The panel selection criteria was based on the 212 
overall genetic difference (p distance) and representation of amino acid variability found in all gt1 213 
E1E2 sequences registered with the Los Alamos HCV sequence database. Analysis of >3800 gt1 214 
E1E2 sequences in the database identified 400aa residues that were conserved in at least 90% of 215 
sequences; of these the majority (306aa) are conserved in 99% of sequences. 154aa were found to be 216 
variable in more than 10% of gt1 E1E2 sequences.  Eleven infectious sequences including the 217 
reference gt1a sequence H77 and ten-patient derived E1E2 sequences from nine HCV-infected 218 
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individuals were selected for inclusion in the gt1 panel Accession numbers: AF011751, AY734976, 219 
AY734971.1, AY734968.1, EU155192.1 and KU645403 to KU645407. These sequences represent 220 
the variability at 145/154 variable residues. In addition, 31aa residues represent minor variants found 221 
in fewer than 10% of sequences in the database.  222 
 223 
Cross-genotypic antibody reactivity is associated with lower viral load. Patient IgG reactivity to 224 
whole E1E2 from Panel XG was tested by ELISA. Relative binding strength based on absorbance 225 
readings normalized to an AP33 standard curve were ranked from 1 (highest) to 51 (lowest) for each 226 
gt; all gt ranks were combined and a final rank position assigned (Table 2). This gave an overall 227 
indication of the relative binding breadth for each patient. The cohort was divided in half by binding 228 
rank and the top ranked half compared to the lower half to determine any clinical associations with 229 
breadth of antibody binding. Those with broader ELISA reactivity profiles had a significantly lower 230 
viral load (P=0.03, Fig. 2A). Individuals with a broader breadth of binding were more often infected 231 
with gt1 HCV and conversely individuals with a narrower breadth of binding were more often 232 
infected with gt3 HCV (P=0.04; P=0.04; Supporting Table S3). These associations appear to be 233 
independent as there was no association between gt of infection and viral load (Supporting Table S3, 234 
P=0.59). 235 
 236 
Neutralization is not associated with viral load. Purified IgGs derived from the CHCV cohort were 237 
tested for their ability to neutralize HCVpp bearing envelope proteins from Panel XG and HCVcc 238 
bearing envelope proteins from Gt1a (1A-HQL), Gt2a-JFH-1 and Gt2b.1.1 (Table 3). In accordance 239 
with Urbanowicz and coworkers we found that HCVpp were more readily neutralized than HCVcc 240 
(25). Therefore neutralization was categorized as a reduction in infectivity of 50% in the HCVpp 241 
system and 40% in the HCVcc system. In both systems, gt2B.1.1 was particularly resistant to 242 
neutralization. The breadth of neutralization of HCVpp Panel XG, defined as broad (neutralization of 243 
>3/6 genotypes) or narrow (<4/6 genotypes), was analyzed for association with clinical factors. 244 
Twenty (40%) of the 51 individuals tested had broad cross-genotypic neutralizing IgGs. There were 245 
no significant associations of breadth of cross-genotypic neutralization with viral load (Fig. 2B). 246 
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Similarly, IgG from 20 CHCV individuals with gt1 infection were tested for neutralizing activity 247 
against Panel Gt1 (Table 4) and the number of pseudoparticles neutralized to the 50% level by each 248 
individual calculated. Neutralization of >7/11 strains was defined as ‘broad’ while ‘narrow’ 249 
neutralization was defined as <8/11 strains. As with Panel XG, there was no association between 250 
breadth of neutralization of Panel Gt1 and viral load (Fig. 2B). 251 
 252 
Correlation between ELISA binding profiles and neutralization. To determine the level of 253 
agreement between the ELISA binding profiles and neutralization activity used to determine antibody 254 
‘breadth’ we calculated non-parametric correlation co-efficients between the assays. For the full 255 
cohort there was a modest correlation of cross-genotypic ELISA binding rank with number of 256 
genotypes neutralized in Panel XG and Panel Gt1 (Spearman’s Rho correlation co-efficient -0.31, 257 
P=0.03 and -0.49, P=0.03, respectively) (Figs. 3A, 3B). Neutralization was determined for the full 258 
cohort against HCVpp and HCVcc (Table 3). Overall there was a significant correlation between the 259 
neutralization rank in both systems (Spearman’s Rho correlation co-efficient = 0.44, P=0.001, Fig. 260 
3C). Indeed the strongest neutralizing IgGs efficiently neutralized HCVpp and HCVcc. Interestingly, 261 
IgG isolated from some individuals neutralized HCVcc more effectively than HCVpp and vice versa, 262 
(compare C1021, C1061 with C1046, C1035, Table 3).  There was also a significant correlation 263 
between the proportion of genotypes neutralized in the two HCVpp panels (Spearman’s Rho 264 
correlation co-efficient =0.58 P=0.007, Fig. 3D) for the gt1-infected subgroup. Neutralization is only 265 
one possible mechanism through which HCV-binding antibodies exert potential antiviral selection. 266 
The modest correlation between ELISA binding and neutralization highlights that while an individual 267 
with strong HCV-binding antibodies often has strong neutralizing antibodies this is not always the 268 
case. This disparity is evident in the lack of association between the breadth of neutralizing antibodies 269 
and viral load, despite an association between HCV-binding and viral load. 270 
 271 
Association of increased age and liver fibrosis with narrow intra-genotype neutralization. 272 
Neutralization breadth for Panel XG was not associated with any clinical features (Fig.4A, 4C, 5A, 273 
5C, 5E). Interestingly, analysis of the subgroup of gt1-infected individuals tested against Panel Gt1 274 
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found an association between breadth of neutralization and age since the broadly neutralizing group 275 
was significantly younger (P=0.009; Fig. 5B). However, there was no association of neutralization 276 
breadth with the estimated duration of infection or age of acquisition for the gt1-infected subgroup 277 
(Fig.5D, 5F). Most notably, there was a striking association between breadth of neutralization activity 278 
and liver fibrosis for the gt1-infected subgroup. The broadly neutralizing group had significantly 279 
lower levels of liver fibrosis as determined by transient elastography (P=0.006; Fig. 4B) and fewer 280 
cirrhotic individuals (P=0.02; Fig. 4D). Importantly, the association between neutralization breadth 281 
and Fibroscan readings remained significant when corrected for age (P=0.025, Generalized Linear 282 
Model, SPSS V. 19.0). 283 
 284 
Role of HLA-DQ polymorphisms in predicting antibody neutralization breadth.  A recent study 285 
showed a link between breadth of neutralizing antibodies against acute gt1 HCV infection and a SNP 286 
(designated rs2395522) in an MHC Class II gene, HLA DQB1 involved in antigen presentation (12). 287 
Therefore we analyzed our cohort for any association between this and the number of HCVpp 288 
neutralized in both panels. There was no significant association between presence of these alleles and 289 
the number of HCVpp neutralized in Panel XG (P=0.41; Fig. 6A). However, the presence of the 290 
rs2395522 AA or AT allele was significantly associated with a greater number of HCVpp neutralized 291 
in Panel Gt1 (P=0.038; Fig.6C). There was no association between SNP rs2395522 and liver fibrosis 292 
for either Panel (P=0.2 and P=0.62; Figs. 6B, 6D). In addition, we tested another genetically linked 293 
HLA-DQA2 SNP rs9275224. Here the GG or AG allele was also significantly associated with 294 
increased neutralization breadth in panel Gt1 (P=0.038, data not shown as the graphs are identical due 295 
to the genetic linkage between the SNPs). SNP rs2395522 is present in the intergenic region of HLA-296 
DQB1; the functional consequences are unknown. However, the linked SNP rs9275224 is associated 297 
with autoimmune diseases including systemic sclerosis and rheumatoid arthritis (44, 45). 298 
 299 
E2 epitopes targeted by patient IgG. In an effort to understand the epitopes targeted by the gt1 300 
patient IgGs used for the intra-genotypic analysis, we determined if they competed for binding to E2 301 
with some well-characterized antibodies. The conformational antibodies selected have been 302 
12 
 
characterized as binding to specific hypothetical immunodomains of E2, designated A, B or C. Their 303 
precise locations on E2 have not been identified to date, however, antibodies that bind 304 
immunodomain A including HmAb CBH-4B are non-neutralizing. Antibodies that bind to 305 
immunodomain B (HmAb HC-1, HC-11 and HC-84) and C (HmAb CBH-7) are able to neutralize 306 
HCV. While immunodomain C has not been characterized, immunodomain B has been shown to 307 
contain the CD81 receptor binding site (15). Lastly, the mouse NAb AP33 that binds a linear epitope 308 
(aa412-423) was also selected. The majority of the broadly neutralizing samples were able to 309 
efficiently compete with 3 or more of the E2 antibodies tested, in contrast most of the narrow 310 
neutralizing samples could only compete with 2 or fewer E2 antibodies (Fig. 7A). Interestingly, while 311 
15/20 samples tested competed with HmAb HC-11 at the >50% level, the majority of broadly 312 
neutralizing samples inhibited both HmAbs CBH-7 and HC-11 binding, 6/10 that recognize different 313 
neutralizing immunodomains of E2 compared to 1/10 of narrow neutralizing samples. There was also 314 
a significant association with intra-genotypic 1 neutralization breadth (P=0.004, P=0.002; Fig. 7B). 315 
Together, these data suggest that individuals with a broadly neutralizing phenotype compete with 316 
antibodies at multiple sites on E2. Moreover, they have antibodies that efficiently bind to more than 317 
one neutralizing immunodomain whereas those with a narrow neutralizing profile effectively target 318 
limited numbers of neutralizing epitopes. 319 
 320 
Discussion 321 
Our analysis of a clinical cohort chronically infected with HCV has yielded new insights into the 322 
importance of the antibody response in disease progression and factors associated with functional 323 
breadth of the antibody response. A broad cross-genotype HCV-binding antibody response was 324 
significantly associated with gt1 HCV infection and independently with reduced viral loads. 325 
Importantly these clinical associations with broad HCV-binding were not evident when analyzing the 326 
breadth of neutralization activity, highlighting distinct biological roles for non-neutralizing and 327 
neutralizing anti-HCV antibodies. The association of ELISA binding and lower viral loads could 328 
reflect the presence of antibodies binding to conserved non-neutralizing regions which would help 329 
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clear virus from serum through opsonisation and subsequent phagocytosis as demonstrated by Eren 330 
and coworkers or complement dependent lysis but would not directly inhibit hepatocyte cell entry 331 
(38). Indeed, there is evidence that binding of virus by non-neutralizing antibodies may prevent 332 
neutralization by antibodies targeting epitopes required for cell entry (46). 333 
While no clinical features were significantly associated with broad or narrow neutralization as 334 
characterized using Panel XG, we did observe significant associations using a larger intra-genotype 1 335 
panel. Most importantly, we show that individuals infected with HCV gt1 who are better able to 336 
neutralize an HCVpp panel incorporating different gt1 E1E2 sequences are less likely to have 337 
cirrhosis or significant liver fibrosis. The panel is composed of strains collected in the UK over the 338 
past decade from different geographical locations and incorporating changes at the majority of 339 
variable aa positions observed within a large sequence database. Therefore this panel represents the 340 
most common viable aa substitutions that may occur within host virus. 341 
 342 
The association with lower levels of liver fibrosis with bNAbs is insufficient evidence alone to 343 
demonstrate a protective effect. However, this adds to case studies which have suggested that 344 
individuals with genetic or iatrogenic suppression of the antibody response show more rapid liver 345 
disease progression (47, 48). It is biologically plausible that individuals possessing antibodies capable 346 
of preventing spread of new variants of their infecting HCV strain may have a degree of protection 347 
from liver injury. Interestingly this ‘broadly neutralizing’ group was also significantly younger. This 348 
may suggest that the higher levels of liver fibrosis observed in the narrow neutralizing group was 349 
simply caused by longer duration of infection. However, we found no difference in duration of 350 
infection between the broad and narrow neutralizing groups and importantly the association between 351 
neutralization breadth and reduced fibrosis remained significant when corrected for age. There is 352 
already evidence that those infected in older age have more rapid disease progression (49) and that B-353 
cell repertoire narrows with age (50). Therefore, this may also reflect an ageing effect on NAb 354 
responses.  355 
 356 
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Although the association of neutralization breadth in Panel Gt1 and host factors was clear, these were 357 
not as apparent in Panel XG. It is not clear from our data if the associations are indeed gt1-specific or 358 
simply caused by limitations due to smaller numbers of genotypes used to determine ‘breadth’ in the 359 
cross-genotypic panel. Although there was a significant correlation between the numbers of HCVpp 360 
isolates neutralized in both panels, some individuals who had narrow cross-genotypic neutralization 361 
profiles showed broad neutralization activity against Panel Gt1 suggesting that some bNAbs may be 362 
gt1-specific.  363 
 364 
No association between levels of E1E2 binding and fibrosis was found. Unlike an earlier study (51), 365 
we found no relationship between antibody binding to the autologous genotype and clinical outcomes 366 
although there was a trend towards cirrhosis in gt1-infected individuals with poor binding to gt1a 367 
E1E2 (P=0.10, data not shown). Combined with the neutralization panel data, this suggests that if 368 
anti-envelope antibodies do have a protective effect, this is most marked where the antibodies target 369 
regions necessary for virus entry.  370 
 371 
We have demonstrated that a NAb response is not closely correlated with the extent of patient IgGs 372 
binding to the whole E1E2 molecule, suggesting that some individuals preferentially target important 373 
neutralization epitopes.  Our data also suggests that those gt1-infected individuals who mount a 374 
broadly neutralizing response effectively direct antibodies at more than one neutralizing domain on 375 
E2. In contrast, those with a narrower neutralizing response appear to target only one region, that 376 
recognized by the HmAb HC-11. It is possible however, that the narrow neutralizing samples do 377 
contain antibodies that target other neutralizing epitopes albeit at a lower concentration or with lower 378 
affinity than found in the broadly neutralizing group. Previous studies have shown that different 379 
regions of E2 interact to prevent neutralization, therefore it is likely that an antibody response 380 
interfering with multiple regions of E2 maybe more effective than a response targeting one epitope 381 
alone (52). Furthermore, Carlsen et al recently showed synergy in neutralization using a combination 382 
of two antibodies against differing domains (53). Our identification of epitopes targeted was 383 
constrained by the panel of monoclonal antibodies used. However, alternative methods such as 384 
15 
 
peptide and phage display capture have limited ability to detect antibodies directed at discontinuous 385 
epitopes (21) therefore our data are a valuable complement to information from these studies. 386 
 387 
While there are many possible explanations for why individuals might preferentially respond to 388 
particular epitopes, we have confirmed that SNP rs2395522 in the HLA-DQB1 gene is associated 389 
with the development of bNAbs in gt1-infected patients (12).  HLA-DQB1 genotype has already been 390 
identified as one of the host factors known to influence outcome of HCV infection in Caucasian 391 
populations (54).  This may be due to restriction in antigen presenting cell presentation of epitopes to 392 
CD4 cells or may involve another mechanism. In contrast, we did not observe an association of this 393 
SNP with neutralization capability across pseudoparticles of other genotypes. In particular, there was 394 
no association of the SNP with the ability of IgG from gt3-infected individuals to neutralize our 395 
standard gt3a HCVpp (P=0.45, data not shown). This may be due to the limitations of testing one gt3 396 
isolate, alternatively it is possible that other HLA genes could be more important for adaptive 397 
responses to other genotype infections. Further studies will be required to distinguish between these 398 
possibilities. 399 
 400 
Our study demonstrates that broad anti-HCV neutralizing responses are associated with lower levels 401 
of liver fibrosis, raising the possibility for a protective role in chronic infection. Our data also show 402 
strong indications that potent neutralizing responses target multiple key regions of E2 rather than a 403 
single epitope. This has significant implications for HCV vaccine design suggesting that a successful 404 
vaccine must induce NAbs to different regions of E2. If we aim to produce a universally protective 405 
vaccine for HCV, a deeper understanding of the role of host genotype and presented epitope sequence 406 
in determining breadth of antibody response requires further exploration across a wider range of 407 
isolates from differing genotypes before vaccine candidates are tested on a wider scale. 408 
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Table 1: Demographics of Cohorts 424 
DEMOGRAPHICS 
CHCV (n=51) 
Number Percentage /Range 
Age, Median (range) 46 (28-68) 
Gender (M/F), No. male (%) 35 (68.6) 
Ethnicity, Caucasian (%) 47 (92.2) 
Source of infection, No. IVDU (%) 32 (62.7) 
Estimated duration of infection (years), Median (range) 25 (2-58) 
IL28B CC genotype, (rs12979860) (%) 17 (35.4)* 
Anti-HBc positive, (%) 11 (24.4)** 
BMI (kg/m2), Mean (range) 26 (19-31.5) 
Diabetes, Present (%) 2 (3.92) 
Previously exposed to interferon based treatment$, (%) 21 (46.7)** 
HCV RNA load pre-treatment  IU/ml, Median (range) 6.8x105 (2272 - 1.1x107) 
Cirrhosis, Present (%) 18 (36) 
Transient elastography (kPa), Median (range) 9 (4-75) 
 425 
*3 subjects not tested **no information available for 6 subjects. $All individuals had HCV infection at 426 
the time of testing, those previously exposed to interferon were either relapsers or null responders. No 427 
individuals were on therapy at the time of sampling.  428 
Table 2: ELISA binding of CHCV cohort to cross-genotypic E1E2 panel. 429 
 Gt 1A 
(rank) 
Gt 1B 
(rank) 
 
Gt 2A 
(rank) 
Gt 2B 
(rank) 
Gt 3A 
(rank) 
Gt 4 
(rank) 
Overall 
rank 
C1001 6.75 (19) 33.07 (2) 1.44 (11) 2.32 (8) 7.73 (19) 5.92 (19) 6 
C1002 0.39 (50) 0.40 (51) 0.06 (51) 0.02 (51) 3.63 (33) 0.05 (48) 50 
C1003 13.36 (12) 18.70 (9) 2.77 (6) 0.60 (15) 61.91 (1) 67.63 (2) 1 
C1006 4.92 (24) 6.02 (31) 0.34 (31) 0.12 (29) 4.90 (29) 1.84 (37) 34 
C1008 1.53 (39) 10.75 (21) 0.38 (27) 0.16 (21) 57.21 (2) 0.64 (46) 28 
C1009 1.46 (41) 7.36 (27) 0.39 (25) 0.10 (36) 27.32 (4) 0.57 (47) 33 
C1010 86.76 (1) 5.17 (34) 0.42 (22) 0.14 (25) 2.15 (41) 4.16 (24) 27 
C1012 31.43 (7) 13.80 (15) 0.55 (17) 0.44 (17) 23.09 (6) 50.27 (3) 4 
C1013 3.57 (28) 6.01 (32) 0.20 (45) -0.15 (49) 3.24 (35) 2.70 (34) 42 
C1015 0.94 (46) 9.19 (25) 0.43 (21) 0.15 (23) 34.57 (3) 4.02 (27) 26 
C1016 7.94 (17) 13.10 (19) 0.65 (15) 0.23 (18) 19.64 (9) 17.69 (7) 9 
C1018 8.25 (16) 14.50 (13) 0.37 (28) 0.19 (19) 7.11 (22) 6.57 (17) 15 
C1020 2.38 (33) 3.01 (43) 0.33 (33) 0.10 (35) 22.09 (8) 0.72 (45) 36 
C1021 26.58 (8) 13.18 (18) 1.23 (12) 3.05 (5) 3.43 (34) 27.45 (4) 7 
C1022 39.09 (4) 4.54 (37) 0.26 (40) 0.08 (39) 2.41 (40) 9.83 (11) 29 
C1023 14.28 (10) 13.46 (16) 0.15 (49) 0.12 (28) 16.76 (10) 11.21 (9) 19 
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C1024 2.97 (29) 2.87 (45) 0.33 (32) 0.11 (32) 3.84 (31) 1.15 (41) 40 
C1029 6.45 (21) 12.76 (20) 0.43 (20) 0.10 (37) 22.74 (7) 9.31 (13) 18 
C1030 6.65 (20) 4.86 (35) 0.34 (29) 0.11 (31) 0.78 (49) 1.60 (38) 38 
C1031 34.53 (5) 7.04 (29) 0.77 (14) 0.13 (27) 2.53 (38) 10.70 (10) 20 
C1032 8.39 (15) 10.08 (23) 0.43 (19) 0.09 (38) 6.05 (26) 22.85 (5) 21 
C1033 0.69 (47) 3.67 (40) 0.21 (44) -0.06 (47) 2.43 (39) -0.05 (49) 49 
C1034 6.38 (22) 13.44 (17) 0.38 (26) 0.13 (26) 25.72 (5) 18.91 (6) 11 
C1035 76.17 (2) 8.20 (26) 0.30 (35) 0.12 (30) 2.06 (42) 13.33 (8) 24 
C1036 1.72 (36) 20.77 (6) 1.53 (9) 2.26 (9) 3.77 (32) 5.57 (20) 14
C1037 2.71 (31) 7.14 (28) 0.13 (50) 0.16 (22) 1.50 (44) 3.57 (28) 39
C1038 1.87 (35) 9.74 (24) 0.26 (39) 0.00 (44) 1.34 (47) 2.85 (33) 41 
C1040 12.29 (14) 27.97 (3) 4.51 (3) 4.33 (4) 2.96 (36) 9.78 (12) 5 
C1041 0.98 (45) 5.48 (33) 0.21 (43) -0.06 (46) 8.51 (16) 0.80 (44) 43 
C1042 41.33 (3) 6.02 (30) 0.34 (30) 0.19 (20) 7.42 (20) 9.10 (14) 17 
C1043 1.08 (44) 20.65 (7) 1.88 (7) 2.98 (6) 7.08 (23) 4.52 (23) 12 
C1045 1.56 (38) 3.30 (42) 0.26 (37) -0.04 (45) 0.34 (50) 1.50 (39) 47 
C1046 14.0 (11) 23.83 (5) 1.50 (10) 1.69 (12) 5.65 (27) 6.88 (16) 7 
C1047 32.15 (6) 3.53 (41) 0.26 (38) 0.10 (34) 1.46 (45) 1.95 (36) 37 
C1049 2.69 (32) 1.54 (49) 0.28 (36) 0.14 (24) 10.31 (13) 2.93 (32) 35 
C1050 18.84 (9) 4.29 (38) 0.24 (41) 0.10 (33) 10.53 (12) 95.25 (1) 23 
C1052 0.68 (48) 1.65 (48) 0.17 (48) -0.10 (48) 7.23 (21) -0.84 (50) 48 
C1054 5.78 (23) 2.90 (44) 0.32 (34) 0.06 (40) 15.58 (11) 4.59 (22) 30 
C1055 2.72 (30) 2.56 (46) 0.23 (42) 0.06 (41) 2.85 (37) 1.03 (42) 46 
C1056 3.89 (27) 2.20 (47) 0.20 (46) 0.02 (43) 4.84 (30) 1.36 (40) 45 
C1057 1.11 (43) 1.51 (50) 4.00 (4) 16.45 (1) 1.36 (35) 2.54 (35) 32 
C1060 1.49 (40) 4.79 (36) 21.84 (1) -7.94 (51) 0.21 (51) -5.13 (51) 44 
C1061 6.96 (18) 34.01 (1) 3.93 (5) 6.43 (2) 9.87 (14) 8.07 (15) 2 
C1062 4.68 (26) 19.17 (8) 1.85 (8) 2.46 (7) 9.06 (15) 3.05 (31) 10 
C1063 0.55 (49) 13.81 (14) 0.58 (16) 1.06 (13) 6.26 (25) 4.06 (26) 24 
C1064 0.14 (51) 4.19 (39) 0.19 (47) -0.68 (50) 1.23 (48) 0.97 (43) 51 
C1072 1.16 (42) 10.15 (22) 0.39 (24) 0.71 (14) 1.98 (43) 3.19 (29) 30 
C1074 1.63 (37) 16.45 (10) 0.91 (13) 2.00 (11) 7.91 (18) 5.51 (21) 12 
C1089 2.02 (34) 16.16 (12) 0.44 (18) 2.14 (10) 8.01 (17) 4.14 (25) 16 
C1112 13.35 (13) 25.42 (4) 5.25 (2) 5.53 (3) 6.29 (24) 6.00 (18) 3 
C1128 4.76 (25) 16.26 (11) 0.40 (23) 0.55 (16) 5.56 (28) 3.12 (30) 22 
 430 
Concentration of AP33 (μg/ml) representing the A450nm absorbance in each sample. The E1E2 431 
binding rank, strongest (1) to weakest (51) is shown in brackets. 432 
 433 
Table 3: Neutralization activity of CHCV cohort. 434 
Patient 
IgG 
HCVpp HCVcc Final 
rank Gt  
1A 
Gt  
1B 
 
Gt 
2A 
Gt 
2B 
Gt 
3A 
Gt  
4 
HCV
pp 
rank 
Gt 
1A  
Gt 
2A 
Gt 
2B 
HCV
cc 
rank 
C1001 70.1  45.1  45.8 5.1 47.8 67.3 32 32.5 28.7 17.6 35 34 
C1002 13.7 -6.8 20.9 -4.2 34.2 15.9 51 9.8 6.6 14.7 50 51 
C1003 83.8 61.9 84.4 30.2 66.3 89.6 2 54.7 51.7 13.8 7 2 
C1006 61.2 16.1 54.0 18.3 36.2 77.4 36 26.5 16.8 14.3 47 46 
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C1008 54.6 42.5 65.0 23.7 77.5 73.5 20 29.9 21.4 1.2 51 36 
C1009 50.8 39.3 67.3 20.9 48.4 71.4 28 24.5 28.6 6.3 49 41 
C1010 72.9 51.3 73.1 37.0 45.7 86.1 8 36.5 20.9 20.3 31 18 
C1012 77.7 51.5 84.9 45.4 76.2 86.7 1 44.0 40.0 20.9 8 2 
C1013 85.8 43.3 39.4 30.8 48.9 70.0 25 51.6 24.4 31.1 13 17 
C1015 68.0 37.3 66.7 26.8 48.7 82.9 15 37.9 47.5 15.1 17 12 
C1016 79.9 61.3 88.9 7.4 74.9 89.1 5 42.1 46.0 32.6 6 4 
C1018 76.8 50.8 40.4 -6.2 49.6 79.6 23 31.3 37.7 23.4 27 26 
C1020 56.1 44.7 38.8 5.0 53.0 83.3 31 26.6 37.2 34.0 24 29
C1021 62.7 34.7 55.4 25.7 46.2 88.1 22 44.5 64.2 56.9 1 8
C1022 66.9 49.6 63.3 32.5 51.6 81.3 12 35.6 40.5 31.3 13 10 
C1023 62.8 49.3 67.1 -6.8 73.5 90.1 13 38.6 37.3 9.3 28 20 
C1024 55.4 65.6 72.5 29.0 40.2 76.8 17 35.2 42.1 30.3 16 13 
C1029 46.4 30.9 83.2 13.4 67.1 87.8 18 40.9 36.1 11.9 25 22 
C1030 47.2 33.3 54.9 26.4 27.9 79.6 38 24.5 36.6 8.0 44 44 
C1031 51.7 37.4 11.0 38.2 31.6 75.3 41 40.1 19.3 43.2 22 31 
C1032 72.6 44.8 81.0 40.3 79.1 86.0 11 41.8 54.2 41.4 5 6 
C1033 23.5 68.3 34.4 13.7 27.8 61.9 44 25.7 28.6 26.5 37 43 
C1034 47.3 33.7 47.3 16.6 26.4 59.1 42 30.8 27.1 15.2 40 44 
C1035 80.7 56.0 66.7 45.1 48.3 87.5 5 35.1 25.5 -1.9 45 26 
C1036 67.2 47.7 52.2 23.7 22.5 65.1 35 36.0 17.0 30.8 29 32 
C1037 84.3 54.8 65.5 16.1 61.6 90.9 9 34.0 19.7 26.9 33 21 
C1038 38.6 40.6 77.1 29.4 51.7 79.0 21 38.7 53.4 -12.5 25 24 
C1040 75.3 53.4 34.4 29.6 29.4 63.6 32 30.8 39.8 3.5 39 36 
C1041 66.6 -29.2 43.7 25.8 71.5 71.9 27 33.3 39.9 1.5 37 32 
C1042 67.9 57.0 57.4 39.6 80.2 89.9 4 67.0 65.2 21.8 2 1 
C1043 44.4 45.5 31.7 -4.1 32.9 60.7 48 48.6 35.0 -19.9 31 42 
C1045 64.5 36.3 37.2 36.3 -22.6 65.0 39 51.5 47.5 -10.7 18 30 
C1046 79.4 60.0 62.5 50.2 64.0 82.9 3 39.9 61.8 -3.5 20 8 
C1047 78.2 42.2 40.3 45.6 62.9 71.4 26 46.3 57.0 5.9 10 15 
C1049 58.1 24.0 66.8 45.0 50.3 82.0 14 42.0 48.8 12.8 12 11 
C1050 84.4 49.5 51.5 45.5 54.3 76.2 9 59.6 60.3 21.8 4 5 
C1052 62.0 -29.6 34.5 14.3 19.7 54.2 49 34.5 35.8 -5.6 42 49 
C1054 13.6 -5.0 39.1 5.5 37.1 82.7 46 41.6 38.8 10.1 23 35 
C1055 61.5 0.2 32.1 1.7 53.7 79.2 37 33.8 43.0 -3.6 35 38 
C1056 73.8 0.3 53.1 21.4 50.1 73.3 28 45.4 54.2 9.6 9 16
C1057 41.3 49.1 60.4 29.4 56.8 70.0 24 36.4 44.4 14.5 21 23 
C1060 67.0 38.2 49.7 31.2 45.9 65.8 34 43.1 39.6 11.7 18 28 
C1061 65.2 55.5 46.0 31.9 52.8 75.8 16 52.1 50.5 38.5 3 7 
C1062 46.3 60.5 10.2 0.3 41.2 60.2 45 39.4 21.4 14.6 30 40 
C1063 27.8 32.4 39.1 15.2 43.5 72.2 42 22.1 38.1 -11.7 48 48 
C1064 24.6 37.9 31.8 12.6 34.1 48.2 50 16.6 30.8 10.9 46 50 
C1072 72.5 47.2 39.2 21.8 28.8 60.2 40 37.2 34.1 11.3 33 39 
C1074 61.3 37.4 41.0 34.1 37.2 76.0 28 42.5 38.0 24.1 11 18 
C1089 28.4 23.9 23.6 26.4 44.9 60.5 47 38.4 30.9 -6.6 41 47 
C1112 71.1 48.1 63.5 38.9 50.3 69.8 19 50.0 36.4 17.5 15 14 
C1128 81.7 70.3 48.1 39.0 65.9 81.9 7 32.6 39.2 -33.7 42 25 
 435 
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Relative neutralization activity (%) is shown, neutralization HCVpp >50%, HCVcc >40% is shown in 436 
blue, <20% neutralization is shown in red. The neutralization rank within the cohort, strongest (1) to 437 
weakest (51) is shown for neutralization of HCVpp, HCVcc and the final overall rank.  438 
Table 4: Gt 1 specific neutralization activity of gt 1 panel. 439 
 
Patient 
IgG 
Gt 1 HCVpp No. 
Neut 
>50% 
1A 
H77 
UKN 
1B 
5.23 
UKN 
1A 
14.38 
UKN 
1A 
14.43 
UKN 
1B 
14.818 
UKN 
1A 
20.8 
GC 
12.02 
GC 
13.01 
GC 
34.11 
GC 
37.04 
ET10 
C1001 70.1 45.1 72.0 60.6 80.5 10.6 29.3 44.6 52.4 53.4 72.9 7 
C1002 13.7 -6.8 -13.1 -22.0 0.11 -8.8 -17.1 -24.1 -7.6 1.6 -13.1 0 
C1003 83.8 61.9 54.4 64.1 88.6 25.4 57.2 54.5 53.1 84.5 90.2 10 
C1010 72.9 51.3 46.1 55.8 87.0 17.7 43.7 41.4 54.8 76.6 69.5 7 
C1012 77.7 51.5 75.7 57.9 87.1 23.7 53.6 49.5 66.6 84.4 78.7 9 
C1013 85.8 43.3 66.6 72.2 80.9 37.2 61.2 58.3 89.0 80.6 88.0 9 
C1016 79.9 61.3 66.2 49.3 94.0 44.0 50.2 40.5 63.5 75.3 88.7 8 
C1022 66.9 49.6 48.9 46.4 64.7 24.1 54.7 53.1 55.1 65.7 75.6 7 
C1023 62.8 49.3 56.1 68.5 72.1 17.2 73.5 64.8 75.9 70.9 76.8 9 
C1030 47.2 33.3 27.3 20.1 62.9 16.5 23.1 20.4 21.3 47.9 59.6 2 
C1031 51.7 37.4 55.7 55.5 70.1 27.6 46.2 64.3 72.3 72.2 67.8 8 
C1032 72.6 44.8 80.6 81.7 89.7 27.6 57.2 69.5 89.2 73.7 74.4 9 
C1034 47.3 33.7 24.0 24.5 50.3 18.1 31.9 3.9 21.6 53.4 41.7 2 
C1035 80.7 56.0 61.0 61.9 76.0 44.7 66.6 64.6 70.9 67.2 82.5 10 
C1036 67.2 47.7 41.6 50.0 57.5 28.3 50.7 43.8 55.4 69.1 69.5 7 
C1037 84.3 54.8 53.7 34.3 76.8 16.2 44.6 41.5 79.2 62.1 75.0 7
C1045 64.5 36.3 29.1 28.2 69.6 0.2 33.1 29.6 52.8 47.9 49.5 3
C1047 78.2 42.2 56.0 57.8 83.3 3.6 51.5 35.4 50.7 62.8 76.8 8 
C1072 72.5 47.2 39.5 44.3 61.3 22.8 42.0 25.6 68.2 59.1 65.7 5 
C1112 71.1 48.1 52.4 71.3 73.2 25.7 71.3 56.7 78.7 75.0 81.6 9 
 440 
Relative neutralization activity (%) is shown, neutralization >50% is shown in blue, <20% 441 
neutralization is shown in red. 442 
 443 
Figure 1: Molecular Phylogenetic analysis of gt 1 E1E2 sequences. Maximum Likelihood method 444 
based on analysis of E1E2 amino-acid sequences using the JTT matrix-based model (55). A discrete 445 
Gamma distribution was used to model evolutionary rate differences among sites (5 categories (+G, 446 
parameter = 0.3680)).The tree with the highest log likelihood (-7055.2655) is shown. The tree is 447 
drawn to scale with the genetic distance for each branch length indicated by the scale bar. Bootstrap 448 
analysis with 1000 replicates was performed. Branches with >70% bootstrap support are labelled. 449 
Sequences classified as functional in the HCVpp system are labelled in blue, non-functional 450 
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sequences in red and sequences included in the gt 1 panel in green. Evolutionary analyses were 451 
conducted in MEGA6 (56) .  452 
 453 
Figure 2: Association of viral load with E1E2 binding and neutralization profiles. (A) The 454 
relative binding of CHCV cohort IgG to E1E2 from 6 subgenotypes of HCV was determined by 455 
ELISA. The IgG samples were ranked from 1 to 51 according to their binding signal for each 456 
subgenotype. The sum of these ranks was used to order the samples from highest cross-genotypic 457 
binding to lowest.  The binding of the upper half of the cohort was regarded as “Broad” and that of the 458 
lower half as “Narrow”. The viral load of the two groups was compared using the Mann Whitney U 459 
test. (B) Neutralization of HCVpp in both panels at the 50% level by purified IgG was determined. 460 
The full CHCV cohort was analyzed against Panel XG and 20 gt 1-infected individuals were tested 461 
against Panel Gt1. The Mann Whitney U test was used to compare viral load between broad 462 
neutralizers, those that neutralized > 3 HCVpp (n=19) in Panel XG and >7 gt 1 HCVpp (n=10) in 463 
Panel Gt1 and narrow neutralizers, that neutralized <4 genotypes (n=32) in Panel XG and <8 gt 1 464 
HCVpp (n=10) in Panel Gt1.  465 
 466 
Figure 3: Non-parametric correlation between E1E2 ELISA binding and neutralization. For 467 
each Panel the number of HCVpp neutralized was plotted against ELISA binding rank, Panel XG (A) 468 
and Panel Gt1 (B). (C) Neutralization activity of the full cohort was analyzed against Panel XG and 3 469 
viruses and the neutralization rank in the HCVcc and HCVpp systems plotted.(D) For those gt1-470 
infected individuals tested in both Panels, the number of HCVpp isolates neutralized in Panel XG was 471 
plotted against the number of HCVpp isolates neutralized in Panel Gt1.The Spearman’s rho 472 
correlation coefficient was calculated for all graphs.  473 
 474 
Figure 4: Association of liver fibrosis with neutralization. Neutralization of Panel XG by the full 475 
CHCV cohort IgGs (A, C) or Panel Gt1 by IgGs from the gt1-infected subgroup (B, D) was 476 
determined as described in Fig. 2. (A, B) Broad and narrow neutralizing groups were defined as in 477 
Fig. 2 and transient elastography (kPa) values measured using Fibroscan® were compared using the 478 
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Mann Whitney U test. (C, D) The number of HCVpp isolates neutralized by IgG from individuals 479 
with and without cirrhosis was compared using the Mann Whitney U test.  480 
 481 
Figure 5: Association of age with breadth of neutralization. We compared the age of individuals in 482 
the broad and narrow neutralizing groups as characterized in Fig. 2 for the full CHCV cohort with 483 
Panel XG (A) and the gt1 subgroup for Panel Gt1 (B) using the Mann Whitney U test. Similarly, the 484 
broad and narrow neutralizing groups were compared for duration of infection (estimated) and age at 485 
acquisition (estimated) for the full CHCV cohort (C, E) and the gt1 subgroup (D, F) respectively. 486 
Note that, no data was available for 6 broad and 10 narrow neutralizing individuals in the full CHCV 487 
cohort and 4 broad and 4 narrow neutralizing individuals in the gt1 subgroup. 488 
 489 
 490 
Figure 6: Association of rs2395522 SNP genotype with breadth of neutralization and liver 491 
fibrosis. All individuals in the CHCV cohort were typed for the HLA DQ-B1 SNP rs2395522. The 492 
Mann-Whitney U test was used to compare SNP type with the number of HCVpp isolates neutralized 493 
in Panel XG (A) and Panel Gt1 (C) panel. Similarly, SNP type was compared to the level of liver 494 
fibrosis as measured by transient elastography (kPa) values for the whole CHCV cohort (B) or the gt 1 495 
subgroup (D) by the Mann Whitney U test.  496 
 497 
Figure 7. Competition of patient IgG with monoclonal antibodies to known epitopes on E2. (A) 498 
Competition ELISA of gt1 patient IgG with E2 mAbs CBH-4B, HC-84, AP33, CBH-7, HC-1 and 499 
HC-11 was performed. The mean percentage of competition (i.e. reduction in mAb binding) from 3 500 
independent experiments is shown. (B) Association of competition with Hmabs CBH-7 and HC-11 501 
for broad (>7 Gt1) and narrow (<8 Gt1) neutralizing samples using the Mann Whitney U test. 502 
 503 
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